Last reviewed · How we verify

NCT04254094: NEODEM

A Cohort Study of Early Onset Neurodegenerative Dementias Prognostic Factors

Active, enrolled Last updated 6 October 2023
What this trial tests

trial testing Neuropsychological scales in Dementia in 163 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 May 2020
Primary endpoint
20 May 2026
20 May 2026

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment163
Start date20 May 2020
Primary completion20 May 2026
Estimated completion20 May 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

Adults 18 to 65, any sex, with Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

NEODEM is a multicenter cohort study of patients with early-onset degenerative dementia (before age 65), the main objective of which is to study behavioral disorders and in particular depression as functional prognostic factors at 3 years.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Design and baseline findings of the NEODEM prospective cohort on early-onset neurodegenerative dementia.
    Auriacombe S, Durand E, Kret M, Cartz-Piver L, et al · · 2026 · PMID 42164618 · DOI 10.1002/dad2.70361

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04254094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing